Article
CYP2C19 but not CYP2B6, CYP3A4, CYP3A5, ABCB1, PON1 or P2Y12 genetic polymorphism impacts antiplatelet response after clopidogrel in Koreans.
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis - 1 Jan 2017
Zhang Hong-Zhe, Kim Moo Hyun, Guo Long-Zhe, Serebruany Victor
Abstract excerpt
Clopidogrel response variability (CRV) is well documented, and may affect clinical outcomes. Impact of genetic polymorphisms is important for assessing and predicting CRV. The extensive evidence indicates the importance of CYP2C19 variants in reducing efficacy of clopidogrel. This study defined the impact of numerous genetic polymorphisms on CRV before and after percutaneous coronary interventions (PCI)...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
